Details of the Drug

General Information of Drug (ID: DMPI98T)

Drug Name
Doxepin
Synonyms
Zonalon; doxepin; Doxepine; Doxepinum [INN-Latin]; Doxepina [INN-Spanish]; Doxepin [USAN]; trans-doxepin; (e)-doxepin; 1668-19-5; Quitaxon; MF 10; UNII-851NLB57HQ; Sinequan; CCRIS 9176; HSDB 3069; Sinequan (TN); Cidoxepina; Cidoxepinum; 851NLB57HQ; 11-(3-(Dimethylamino)propylidene)-6H-dibenz(b,e)oxepine; 11-(3-Dimethylaminopropylidene)-6,11-dihydrodibenz(b,e)oxipin; 11-(3-Dimethylamino-propyliden)-6,11-dihydro-dibenz(b,e)oxipin; N,N-Dimethyldibenz(b,e)oxepin-delta(11(6H),gamma)-propylamine; Cidoxepin [INN]; Curatin; Adapin; Cidoxepin; Doxepina; Doxepinum; Triadapin; Doxepin Hydrochloride; MOLI001594; Adapine (TN); Aponal (TN); Cis-doxepin; Deptran (TN); Doxepin (INN); Doxepin, Hydrochloride; Sinquan (TN); Xepin (TN); Zonalon (TN); Doxepin (Z)-isomer; Cis-N-(3-(6H-Dibenz(b,e)oxepin-11-yliden)propyl)-N,N-dimethylamin; (3E)-3-(6H-benzo[c][1]benzoxepin-11-ylidene)-N,N-dimethylpropan-1-amine; (3E)-3-dibenzo[b,e]oxepin-11(6H)-ylidene-N,N-dimethylpropan-1-amine; (3Z)-3-(6H-benzo[c][1]benzoxepin-11-ylidene)-N,N-di(methyl)propan-1-amine; (3Z)-3-(6H-benzo[c][1]benzoxepin-11-ylidene)-N,N-dimethylpropan-1-amine; (3Z)-3-dibenzo[b,e]oxepin-11(6H)-ylidene-N,N-dimethylpropan-1-amine; (Z)-Doxepin; 3-(6H-benzo[c][1]benzoxepin-11-ylidene)-N,N-dimethylpropan-1-amine; 3-Dibenz[b,e]oxepin-11(6H)-ylidene-N,N-dimethyl-1-propanamine; 3-dibenzo[b,e]oxepin-11(6H)-ylidene-N,N-dimethylpropan-1-amine; [11C]doxepin
Indication
Disease Entry ICD 11 Status REF
Depression 6A70-6A7Z Approved [1], [2]
Therapeutic Class
Antidepressants
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 279.4
Topological Polar Surface Area (xlogp) 4.3
Rotatable Bond Count (rotbonds) 3
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 2
ADMET Property
Absorption AUC
The area under the plot of plasma concentration (AUC) of drug is 25.5 mgh/L [3]
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 12.72 mg/L [3]
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 0.25 h [3]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
Clearance
The clearance of drug is 0.93 L/h/kg [5]
Elimination
Less than 3% of a doxepin dose is excreted in the urine as parent compound or nordoxepin [5]
Half-life
The concentration or amount of drug in body reduced by one-half in 15 hours [6]
Metabolism
The drug is metabolized via the transformation of N-desmethyldoxepin to its glucuronide conjugates [7]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 17.89643 micromolar/kg/day [8]
Unbound Fraction
The unbound fraction of drug in plasma is 0.2% [6]
Vd
The volume of distribution (Vd) of drug is 20 L/kg [9]
Chemical Identifiers
Formula
C19H21NO
IUPAC Name
(3E)-3-(6H-benzo[c][1]benzoxepin-11-ylidene)-N,N-dimethylpropan-1-amine
Canonical SMILES
CN(C)CC/C=C/1\\C2=CC=CC=C2COC3=CC=CC=C31
InChI
InChI=1S/C19H21NO/c1-20(2)13-7-11-17-16-9-4-3-8-15(16)14-21-19-12-6-5-10-18(17)19/h3-6,8-12H,7,13-14H2,1-2H3/b17-11+
InChIKey
ODQWQRRAPPTVAG-GZTJUZNOSA-N
Cross-matching ID
PubChem CID
667477
CAS Number
1668-19-5
DrugBank ID
DB01142
TTD ID
D06FES
VARIDT ID
DR00542
INTEDE ID
DR0544
ACDINA ID
D00626

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Histamine H1 receptor (H1R) TTTIBOJ HRH1_HUMAN Inhibitor [10], [11]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [12]
Cytochrome P450 2D6 (CYP2D6)
Main DME 		DECB0K3 CP2D6_HUMAN Substrate [13]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Substrate [14]
Mephenytoin 4-hydroxylase (CYP2C19)
Main DME 		DEGTFWK CP2CJ_HUMAN Substrate [14]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Substrate [12]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Depression
ICD Disease Classification 6A70-6A7Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Histamine H1 receptor (H1R) DTT HRH1 6.74E-01 0.13 0.43
Cytochrome P450 1A2 (CYP1A2) DME CYP1A2 8.46E-01 -6.63E-03 -4.49E-02
Mephenytoin 4-hydroxylase (CYP2C19) DME CYP2C19 9.62E-01 2.57E-02 1.10E-01
Cytochrome P450 2D6 (CYP2D6) DME CYP2D6 8.70E-01 2.98E-02 1.22E-01
Cytochrome P450 2C9 (CYP2C9) DME CYP2C9 2.35E-01 2.78E-02 2.09E-01
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 1.76E-01 1.26E-01 8.27E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Doxepin
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Vilazodone DM4LECQ Major Additive serotonergic effects by the combination of Doxepin and Vilazodone. Depression [6A70-6A7Z] [65]
Nefazodone DM4ZS8M Major Additive serotonergic effects by the combination of Doxepin and Nefazodone. Depression [6A70-6A7Z] [66]
Vortioxetine DM6F1PU Major Additive serotonergic effects by the combination of Doxepin and Vortioxetine. Depression [6A70-6A7Z] [66]
Isocarboxazid DMAF1NB Major Additive serotonergic effects by the combination of Doxepin and Isocarboxazid. Depression [6A70-6A7Z] [67]
Milnacipran DMBFE74 Major Additive serotonergic effects by the combination of Doxepin and Milnacipran. Depression [6A70-6A7Z] [66]
Escitalopram DMFK9HG Major Additive serotonergic effects by the combination of Doxepin and Escitalopram. Depression [6A70-6A7Z] [68]
Desvenlafaxine DMHD4PE Major Additive serotonergic effects by the combination of Doxepin and Desvenlafaxine. Depression [6A70-6A7Z] [66]
OPC-34712 DMHG57U Moderate Additive anticholinergic effects by the combination of Doxepin and OPC-34712. Depression [6A70-6A7Z] [69]
Clomipramine DMINRKW Moderate Additive anticholinergic effects by the combination of Doxepin and Clomipramine. Depression [6A70-6A7Z] [70]
Esketamine DMVU687 Moderate Additive CNS depression effects by the combination of Doxepin and Esketamine. Depression [6A70-6A7Z] [71]
⏷ Show the Full List of 10 DDI Information of This Drug
Coadministration of a Drug Treating the Disease Different from Doxepin (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Methylene blue DMJAPE7 Major Additive serotonergic effects by the combination of Doxepin and Methylene blue. Acquired methaemoglobinaemia [3A93] [67]
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Doxepin and Ivosidenib. Acute myeloid leukaemia [2A60] [72]
Midostaurin DMI6E0R Moderate Increased risk of prolong QT interval by the combination of Doxepin and Midostaurin. Acute myeloid leukaemia [2A60] [73]
Idarubicin DMM0XGL Moderate Increased risk of prolong QT interval by the combination of Doxepin and Idarubicin. Acute myeloid leukaemia [2A60] [73]
Arn-509 DMT81LZ Moderate Increased risk of prolong QT interval by the combination of Doxepin and Arn-509. Acute myeloid leukaemia [2A60] [74]
Gilteritinib DMWQ4MZ Moderate Increased risk of prolong QT interval by the combination of Doxepin and Gilteritinib. Acute myeloid leukaemia [2A60] [75]
Oliceridine DM6MDCF Moderate Additive CNS depression effects by the combination of Doxepin and Oliceridine. Acute pain [MG31] [76]
Mepyramine DMB4SFH Moderate Additive anticholinergic effects by the combination of Doxepin and Mepyramine. Allergic/hypersensitivity disorder [4A80-4A8Z] [70]
Phenyltoloxamine DMKAEQW Moderate Additive anticholinergic effects by the combination of Doxepin and Phenyltoloxamine. Allergic/hypersensitivity disorder [4A80-4A8Z] [70]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Doxepin and Ivabradine. Angina pectoris [BA40] [74]
Bepridil DM0RKS4 Major Increased risk of prolong QT interval by the combination of Doxepin and Bepridil. Angina pectoris [BA40] [77]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Doxepin and Dronedarone. Angina pectoris [BA40] [73]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Doxepin and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [78]
Cilostazol DMZMSCT Moderate Increased risk of prolong QT interval by the combination of Doxepin and Cilostazol. Arterial occlusive disease [BD40] [73]
Posaconazole DMUL5EW Moderate Increased risk of prolong QT interval by the combination of Doxepin and Posaconazole. Aspergillosis [1F20] [73]
Desipramine DMT2FDC Moderate Additive anticholinergic effects by the combination of Doxepin and Desipramine. Attention deficit hyperactivity disorder [6A05] [69]
Ofloxacin DM0VQN3 Moderate Increased risk of prolong QT interval by the combination of Doxepin and Ofloxacin. Bacterial infection [1A00-1C4Z] [79]
Sparfloxacin DMB4HCT Major Increased risk of prolong QT interval by the combination of Doxepin and Sparfloxacin. Bacterial infection [1A00-1C4Z] [80]
Gemifloxacin DMHT34O Moderate Increased risk of prolong QT interval by the combination of Doxepin and Gemifloxacin. Bacterial infection [1A00-1C4Z] [79]
Retigabine DMGNYIH Moderate Increased risk of prolong QT interval by the combination of Doxepin and Retigabine. Behcet disease [4A62] [73]
Cariprazine DMJYDVK Moderate Additive anticholinergic effects by the combination of Doxepin and Cariprazine. Bipolar disorder [6A60] [70]
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of Doxepin and Eribulin. Breast cancer [2C60-2C6Y] [73]
Lapatinib DM3BH1Y Moderate Increased risk of prolong QT interval by the combination of Doxepin and Lapatinib. Breast cancer [2C60-2C6Y] [73]
Alpelisib DMEXMYK Moderate Increased metabolism of Doxepin caused by Alpelisib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [81]
Bosutinib DMTI8YE Moderate Increased risk of prolong QT interval by the combination of Doxepin and Bosutinib. Breast cancer [2C60-2C6Y] [74]
Acetylcholine DMDF79Z Moderate Antagonize the effect of Doxepin when combined with Acetylcholine. Cataract [9B10] [82]
PF-04449913 DMSB068 Moderate Increased risk of prolong QT interval by the combination of Doxepin and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [83]
Umeclidinium DM4E8O9 Moderate Additive anticholinergic effects by the combination of Doxepin and Umeclidinium. Chronic obstructive pulmonary disease [CA22] [84]
Tiotropium DMFDC0Q Moderate Additive anticholinergic effects by the combination of Doxepin and Tiotropium. Chronic obstructive pulmonary disease [CA22] [84]
Revefenacin DMMP5SI Moderate Additive anticholinergic effects by the combination of Doxepin and Revefenacin. Chronic obstructive pulmonary disease [CA22] [84]
Dihydrocodeine DMB0FWL Moderate Additive serotonergic effects by the combination of Doxepin and Dihydrocodeine. Chronic pain [MG30] [76]
Levomilnacipran DMV26S8 Major Additive serotonergic effects by the combination of Doxepin and Levomilnacipran. Chronic pain [MG30] [66]
Mestranol DMG3F94 Minor Decreased metabolism of Doxepin caused by Mestranol. Contraceptive management [QA21] [85]
Halothane DM80OZ5 Moderate Increased risk of prolong QT interval by the combination of Doxepin and Halothane. Corneal disease [9A76-9A78] [73]
Sevoflurane DMC9O43 Moderate Increased risk of prolong QT interval by the combination of Doxepin and Sevoflurane. Corneal disease [9A76-9A78] [71]
Probucol DMVZQ2M Moderate Increased risk of prolong QT interval by the combination of Doxepin and Probucol. Coronary atherosclerosis [BA80] [73]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Doxepin and Pasireotide. Cushing syndrome [5A70] [73]
Osilodrostat DMIJC9X Moderate Increased risk of prolong QT interval by the combination of Doxepin and Osilodrostat. Cushing syndrome [5A70] [74]
Mepenzolate DM8YU2F Moderate Additive anticholinergic effects by the combination of Doxepin and Mepenzolate. Digestive system disease [DE2Z] [70]
5-hydroxy-L-tryptophan DMDWZGJ Major Additive serotonergic effects by the combination of Doxepin and 5-hydroxy-L-tryptophan. Discovery agent [N.A.] [65]
Tetrabenazine DMYWQ0O Moderate Increased risk of prolong QT interval by the combination of Doxepin and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [73]
Deutetrabenazine DMUPFLI Moderate Increased risk of prolong QT interval by the combination of Doxepin and Deutetrabenazine. Dystonic disorder [8A02] [86]
Fosphenytoin DMOX3LB Moderate Decreased metabolism of Doxepin caused by Fosphenytoin mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [87]
Solifenacin DMG592Q Moderate Additive anticholinergic effects by the combination of Doxepin and Solifenacin. Functional bladder disorder [GC50] [69]
Mirabegron DMS1GYT Moderate Decreased metabolism of Doxepin caused by Mirabegron mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [88]
Sunitinib DMCBJSR Moderate Increased risk of prolong QT interval by the combination of Doxepin and Sunitinib. Gastrointestinal stromal tumour [2B5B] [73]
Procarbazine DMIK367 Major Additive serotonergic effects by the combination of Doxepin and Procarbazine. Hodgkin lymphoma [2B30] [89]
Fostemsavir DM50ILT Moderate Increased risk of prolong QT interval by the combination of Doxepin and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [90]
Cobicistat DM6L4H2 Moderate Decreased metabolism of Doxepin caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [91]
Saquinavir DMG814N Major Increased risk of prolong QT interval by the combination of Doxepin and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [92]
Rilpivirine DMJ0QOW Moderate Increased risk of prolong QT interval by the combination of Doxepin and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [73]
Givosiran DM5PFIJ Moderate Decreased metabolism of Doxepin caused by Givosiran mediated inhibition of CYP450 enzyme. Inborn porphyrin/heme metabolism error [5C58] [93]
Belladonna DM2RBWK Moderate Additive anticholinergic effects by the combination of Doxepin and Belladonna. Infectious gastroenteritis/colitis [1A40] [69]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Doxepin caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [94]
ITI-007 DMUQ1DO Moderate Additive anticholinergic effects by the combination of Doxepin and ITI-007. Insomnia [7A00-7A0Z] [69]
Polyethylene glycol DM4I1JP Moderate Increased risk of lowers seizure threshold by the combination of Doxepin and Polyethylene glycol. Irritable bowel syndrome [DD91] [73]
Glycerol phenylbutyrate DMDGRQO Moderate Decreased metabolism of Doxepin caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme. Liver disease [DB90-DB9Z] [74]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Doxepin and Crizotinib. Lung cancer [2C25] [95]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Doxepin and Ceritinib. Lung cancer [2C25] [73]
PF-06463922 DMKM7EW Moderate Increased metabolism of Doxepin caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [71]
Dacomitinib DMOH8VY Moderate Decreased metabolism of Doxepin caused by Dacomitinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [96]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Doxepin and Osimertinib. Lung cancer [2C25] [97]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Doxepin and Selpercatinib. Lung cancer [2C25] [98]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Doxepin and Lumefantrine. Malaria [1F40-1F45] [71]
Halofantrine DMOMK1V Major Increased risk of prolong QT interval by the combination of Doxepin and Halofantrine. Malaria [1F40-1F45] [99]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Doxepin and Hydroxychloroquine. Malaria [1F40-1F45] [100]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of prolong QT interval by the combination of Doxepin and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [74]
Arsenic trioxide DM61TA4 Major Increased risk of ventricular arrhythmias by the combination of Doxepin and Arsenic trioxide. Mature B-cell lymphoma [2A85] [101]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Doxepin and Vemurafenib. Melanoma [2C30] [73]
LGX818 DMNQXV8 Moderate Increased risk of prolong QT interval by the combination of Doxepin and LGX818. Melanoma [2C30] [102]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Doxepin and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [103]
Flibanserin DM70DTN Moderate Additive CNS depression effects by the combination of Doxepin and Flibanserin. Mood disorder [6A60-6E23] [104]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Doxepin and Panobinostat. Multiple myeloma [2A83] [105]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Doxepin and Siponimod. Multiple sclerosis [8A40] [71]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Doxepin and Fingolimod. Multiple sclerosis [8A40] [73]
Ozanimod DMT6AM2 Major Additive serotonergic effects by the combination of Doxepin and Ozanimod. Multiple sclerosis [8A40] [106]
Romidepsin DMT5GNL Moderate Increased risk of prolong QT interval by the combination of Doxepin and Romidepsin. Mycosis fungoides [2B01] [73]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Doxepin caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [74]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Doxepin and Nilotinib. Myeloproliferative neoplasm [2A20] [73]
Dasatinib DMJV2EK Moderate Increased risk of prolong QT interval by the combination of Doxepin and Dasatinib. Myeloproliferative neoplasm [2A20] [71]
Phenindamine DMDTC7R Moderate Additive anticholinergic effects by the combination of Doxepin and Phenindamine. Nasopharyngitis [CA00] [69]
Rolapitant DM8XP26 Moderate Decreased metabolism of Doxepin caused by Rolapitant mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [107]
Cyclizine DM9G7BS Moderate Additive anticholinergic effects by the combination of Doxepin and Cyclizine. Nausea/vomiting [MD90] [69]
Bupropion DM5PCS7 Major Decreased metabolism of Doxepin caused by Bupropion mediated inhibition of CYP450 enzyme. Nicotine use disorder [6C4A] [108]
Entrectinib DMMPTLH Moderate Increased risk of prolong QT interval by the combination of Doxepin and Entrectinib. Non-small cell lung cancer [2C25] [74]
Lorcaserin DMG6OYJ Major Additive serotonergic effects by the combination of Doxepin and Lorcaserin. Obesity [5B80-5B81] [109]
Dexfenfluramine DMJ7YDS Major Additive serotonergic effects by the combination of Doxepin and Dexfenfluramine. Obesity [5B80-5B81] [66]
Levomethadyl Acetate DM06HG5 Major Increased risk of prolong QT interval by the combination of Doxepin and Levomethadyl Acetate. Opioid use disorder [6C43] [74]
Lofexidine DM1WXA6 Moderate Increased risk of prolong QT interval by the combination of Doxepin and Lofexidine. Opioid use disorder [6C43] [74]
Rucaparib DM9PVX8 Moderate Increased risk of prolong QT interval by the combination of Doxepin and Rucaparib. Ovarian cancer [2C73] [73]
Oxymorphone DM65AGJ Moderate Additive CNS depression effects by the combination of Doxepin and Oxymorphone. Pain [MG30-MG3Z] [76]
Dezocine DMJDB0Y Moderate Additive CNS depression effects by the combination of Doxepin and Dezocine. Pain [MG30-MG3Z] [76]
Flavoxate DMKV4NL Moderate Additive anticholinergic effects by the combination of Doxepin and Flavoxate. Pain [MG30-MG3Z] [69]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Doxepin and Triclabendazole. Parasitic worm infestation [1F90] [73]
Safinamide DM0YWJC Major Additive serotonergic effects by the combination of Doxepin and Safinamide. Parkinsonism [8A00] [106]
Rasagiline DM3WKQ4 Major Additive serotonergic effects by the combination of Doxepin and Rasagiline. Parkinsonism [8A00] [89]
Levodopa DMN3E57 Minor Altered absorption of Doxepin due to GI dynamics variation caused by Levodopa. Parkinsonism [8A00] [110]
Pimavanserin DMR7IVC Moderate Increased risk of prolong QT interval by the combination of Doxepin and Pimavanserin. Parkinsonism [8A00] [111]
Orphenadrine DMW542E Moderate Additive anticholinergic effects by the combination of Doxepin and Orphenadrine. Parkinsonism [8A00] [70]
Methylscopolamine DM5VWOB Moderate Additive anticholinergic effects by the combination of Doxepin and Methylscopolamine. Peptic ulcer [DA61] [69]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Doxepin and Macimorelin. Pituitary gland disorder [5A60-5A61] [72]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Doxepin and Lefamulin. Pneumonia [CA40] [112]
Degarelix DM3O8QY Moderate Increased risk of prolong QT interval by the combination of Doxepin and Degarelix. Prostate cancer [2C82] [74]
ABIRATERONE DM8V75C Moderate Decreased metabolism of Doxepin caused by ABIRATERONE mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [113]
Enzalutamide DMGL19D Moderate Increased risk of prolong QT interval by the combination of Doxepin and Enzalutamide. Prostate cancer [2C82] [74]
Relugolix DMK7IWL Moderate Increased risk of prolong QT interval by the combination of Doxepin and Relugolix. Prostate cancer [2C82] [74]
Levomepromazine DMIKFEL Moderate Increased plasma concentrations of Doxepin and Levomepromazine due to competitive inhibition of the same metabolic pathway. Psychotic disorder [6A20-6A25] [114]
Quetiapine DM1N62C Moderate Increased risk of prolong QT interval by the combination of Doxepin and Quetiapine. Schizophrenia [6A20] [73]
Aripiprazole DM3NUMH Moderate Additive anticholinergic effects by the combination of Doxepin and Aripiprazole. Schizophrenia [6A20] [69]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Doxepin and Iloperidone. Schizophrenia [6A20] [73]
Paliperidone DM7NPJS Moderate Increased risk of prolong QT interval by the combination of Doxepin and Paliperidone. Schizophrenia [6A20] [73]
Molindone DMAH70G Moderate Additive anticholinergic effects by the combination of Doxepin and Molindone. Schizophrenia [6A20] [69]
Thiothixene DMDINC4 Moderate Additive anticholinergic effects by the combination of Doxepin and Thiothixene. Schizophrenia [6A20] [69]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Doxepin and Amisulpride. Schizophrenia [6A20] [115]
Asenapine DMSQZE2 Moderate Increased risk of prolong QT interval by the combination of Doxepin and Asenapine. Schizophrenia [6A20] [73]
Armodafinil DMGB035 Moderate Decreased metabolism of Doxepin caused by Armodafinil mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [71]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Doxepin and LEE011. Solid tumour/cancer [2A00-2F9Z] [73]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Doxepin and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [71]
Telavancin DM58VQX Moderate Increased risk of prolong QT interval by the combination of Doxepin and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [73]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Doxepin and Lenvatinib. Thyroid cancer [2D10] [73]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Doxepin and Cabozantinib. Thyroid cancer [2D10] [74]
Trimeprazine DMEMV9D Moderate Increased plasma concentrations of Doxepin and Trimeprazine due to competitive inhibition of the same metabolic pathway. Vasomotor/allergic rhinitis [CA08] [116]
Acrivastine DMTIGA0 Moderate Additive anticholinergic effects by the combination of Doxepin and Acrivastine. Vasomotor/allergic rhinitis [CA08] [69]
Propafenone DMPIBJK Moderate Decreased metabolism of Doxepin caused by Propafenone mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [117]
Flecainide DMSQDLE Moderate Increased risk of prolong QT interval by the combination of Doxepin and Flecainide. Ventricular tachyarrhythmia [BC71] [117]
⏷ Show the Full List of 125 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
Diiodofluorescein E00385 92311 Colorant
FD&C blue no. 1 E00263 19700 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
Quinoline yellow WS E00309 24671 Colorant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sunset yellow FCF E00255 17730 Colorant
Ammonia E00007 222 Alkalizing agent
Butyl alcohol E00011 263 Flavoring agent; Solvent
Ferrosoferric oxide E00231 14789 Colorant
Magnesium stearate E00208 11177 lubricant
Potassium hydroxide E00233 14797 Alkalizing agent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
⏷ Show the Full List of 15 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Sinequan 150 mg capsule 150 mg Oral Capsule Oral
Sinequan 10 mg capsule 10 mg Oral Capsule Oral
Sinequan 100 mg capsule 100 mg Oral Capsule Oral
Sinequan 25 mg capsule 25 mg Oral Capsule Oral
Sinequan 50 mg capsule 50 mg Oral Capsule Oral
Sinequan 75 mg capsule 75 mg Oral Capsule Oral
Sinequan 6 mg tablet 6 mg Oral Tablet Oral
Sinequan 3 mg tablet 3 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1225).
2 Emerging treatments for depression. Expert Opin Pharmacother. 2006 Dec;7(17):2323-39.
3 New zealand perfalgan report
4 BDDCS applied to over 900 drugs
5 Virtanen R, Scheinin M, Iisalo E: Single dose pharmacokinetics of doxepin in healthy volunteers. Acta Pharmacol Toxicol (Copenh). 1980 Nov;47(5):371-6.
6 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
7 Nelis HJ, De Leenheer AP: Metabolism of minocycline in humans. Drug Metab Dispos. 1982 Mar-Apr;10(2):142-6.
8 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
9 An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
10 Novel therapeutic usage of low-dose doxepin hydrochloride. Expert Opin Investig Drugs. 2007 Aug;16(8):1295-305.
11 Evaluation of in vivo selective binding of [11C]doxepin to histamine H1 receptors in five animal species. Nucl Med Biol. 2004 May;31(4):493-502.
12 The N-demethylation of the doxepin isomers is mainly catalyzed by the polymorphic CYP2C19. Pharm Res. 2002 Jul;19(7):1034-7.
13 Doxepin inhibits CYP2D6 activity in vivo. Pol J Pharmacol. 2004 Jul-Aug;56(4):491-4.
14 Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers. Pharmacogenetics. 2002 Oct;12(7):571-80.
15 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
16 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
17 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
18 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
19 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
20 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
21 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
22 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
23 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
24 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
25 Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
26 Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
27 Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
28 PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
29 The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
30 The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
31 Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
32 Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
33 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
34 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
35 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
36 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
37 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
38 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
39 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
40 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
41 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
42 Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
43 Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
44 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
45 Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
46 Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
47 New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
48 A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
49 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
50 High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
51 Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
52 CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
53 Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
54 Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
55 Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
56 Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
57 Cloning and pharmacological characterization of a fourth histamine receptor (H(4)) expressed in bone marrow. Mol Pharmacol. 2001 Mar;59(3):420-6.
58 Clinical research of Ibudilast on treating the steroid resistant allergic rhinitis. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2009 Jan;23(2):63-6.
59 Intact cell binding for in vitro prediction of sedative and non-sedative histamine H1-receptor antagonists based on receptor internalization. J Pharmacol Sci. 2008 May;107(1):66-79.
60 Update on prescription and over-the-counter histamine inverse agonists in rhinitis therapy. Curr Allergy Asthma Rep. 2009 Mar;9(2):140-8.
61 Central effects of cinnarizine: restricted use in aircrew. Aviat Space Environ Med. 2002 Jun;73(6):570-4.
62 Influence of epinastine hydrochloride, an H1-receptor antagonist, on the function of mite allergen-pulsed murine bone marrow-derived dendritic cell... Mediators Inflamm. 2009;2009:738038.
63 Examining the tolerability of the non-sedating antihistamine desloratadine: a prescription-event monitoring study in England. Drug Saf. 2009;32(2):169-79.
64 Emerging drugs for ocular allergy. Expert Opin Emerg Drugs. 2005 Aug;10(3):505-20.
65 Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics." J Clin Psychopharmacol 10 (1990): 48-50. [PMID: 1968472]
66 Achamallah NS "Visual hallucinations after combining fluoxetine and dextromethorphan ." Am J Psychiatry 149 (1992): 1406. [PMID: 1530079]
67 Spiker DG, Pugh DD "Combining tricyclic and monoamine oxidase inhibitor antidepressants." Arch Gen Psychiatry 33 (1976): 828-30. [PMID: 942286]
68 Bhatara VS, Magnus RD, Paul KL, Preskorn SH "Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms." Ann Pharmacother 32 (1998): 432-6. [PMID: 9562139]
69 Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
70 Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
71 Cerner Multum, Inc. "Australian Product Information.".
72 Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
73 Canadian Pharmacists Association.
74 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
75 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
76 Vizcaychipi MP, Walker S, Palazzo M "Serotonin syndrome triggered by tramadol." Br J Anaesth 99 (2007): 919. [PMID: 18006535]
77 Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41. [PMID: 10721388]
78 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
79 Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
80 Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996): 350-1. [PMID: 8781892]
81 Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
82 Multum Information Services, Inc. Expert Review Panel.
83 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
84 Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21. [PMID: 23170031]
85 Edelbroek PM, Zitman FG, Knoppert-van der Klein EA, van Putten PM, de Wolff FA "Therapeutic drug monitoring of amitriptyline: impact of age, smoking and contraceptives on drug and metabolite levels in bulimic women." Clin Chim Acta 165 (1987): 177-87. [PMID: 3652444]
86 Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
87 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
88 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
89 Boyer EW, Shannon M "The serotonin syndrome." N Engl J Med 352 (2005): 1112-20. [PMID: 15784664]
90 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
91 Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
92 Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
93 Product Information. Givlaari (givosiran). Alnylam Pharmaceuticals, Cambridge, MA.
94 Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
95 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
96 Product Information. Vizimpro (dacomitinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
97 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
98 Product Information. Retevmo (selpercatinib). Lilly, Eli and Company, Indianapolis, IN.
99 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
100 Product Information. Hydroxychloroquine Sulfate (hydroxychloroquine). Prasco Laboratories, Cincinnati, OH.
101 Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
102 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
103 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
104 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
105 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
106 Alvine G, Black DW, Tsuang D "Case of delirium secondary to phenelzine/L-tryptophan combination." J Clin Psychiatry 51 (1990): 311. [PMID: 2365671]
107 Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
108 James WA, Lippmann S "Bupropion: overview and prescribing guidelines in depression." South Med J 84 (1991): 222-4. [PMID: 1899294]
109 Product Information. Belviq (lorcaserin). Eisai Inc, Teaneck, NJ.
110 Morgan JP, Rivera-Calimlim L, Messiha F, Sundaresan PR, Trabert N "Imipramine-mediated interference with levodopa absorption from the gastrointestinal tract in man." Neurology 25 (1975): 1029-34. [PMID: 1237820]
111 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
112 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
113 Product Information. Zytiga (abiraterone). Centocor Inc, Malvern, PA.
114 Bock JL, Nelson JC, Gray S, Jatlow PI "Desipramine hydroxylation: variability and effect of antipsychotic drugs." Clin Pharmacol Ther 33 (1983): 322-8. [PMID: 6130865]
115 Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
116 Lee BS "Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs." J Clin Psychiatry 47 (1986): 571. [PMID: 3771507]
117 Katz MR "Raised serum levels of desipramine with the antiarrhythmic propafenone ." J Clin Psychiatry 52 (1991): 432-3. [PMID: 1938981]